Skip to main content

ESTRATEGIAS INNOVADORAS PARA TERAPIA CONTRA CELULAS MADRE TUMORALES: ACTIVANDO RECEPTORES DE DOPAMINA CON NANOPARTICULAS PROTEICAS

PI20/00770

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER)
Execution centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

All-in-one biofabrication and loading of recombinant vaults in human cells

  • Martín, Fernando|||0000-0002-3496-9093
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Bravo, Marlon|||0000-0002-0065-9812
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Nano-based approved pharmaceuticals for cancer treatment, present and future challenges

  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • De la Fuente, Noa
  • Español, Pia|||0000-0002-1164-6355
  • Gámez, Maria
  • Balart, Josep|||0000-0002-1173-7556
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rovira Negre, Ramon|||0000-0003-4136-4153
  • Ruiz, Raúl
  • Martín-Lorente, Cristina|||0000-0002-9827-0521
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe unde-sirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Escherichia coli as a New Platform for the Fast Production of Vault-like Nanoparticles, An Optimized Protocol

  • Fernández, Roger
  • Carreño, Aida|||0000-0001-7725-7515
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Benito, Antoni|||0000-0002-9776-1003
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Vaults are protein nanoparticles that are found in almost all eukaryotic cells but are absent in prokaryotic ones. Due to their properties (nanometric size, biodegradability, biocompatibility, and lack of immunogenicity), vaults show enormous potential as a bio-inspired, self-assembled drug-delivery system (DDS). Vault architecture is directed by self-assembly of the "major vault protein" (MVP), the main component of this nanoparticle. Recombinant expression (in different eukaryotic systems) of the MVP resulted in the formation of nanoparticles that were indistinguishable from native vaults. Nowadays, recombinant vaults for different applications are routinely produced in insect cells and purified by successive ultracentrifugations, which are both tedious and time-consuming strategies. To offer cost-efficient and faster protocols for nanoparticle production, we propose the production of vault-like nanoparticles in Escherichia coli cells, which are still one of the most widely used prokaryotic cell factories for recombinant protein production. The strategy proposed allowed for the spontaneous encapsulation of the engineered cargo protein within the self-assembled vault-like nanoparticles by simply mixing the clarified lysates of the producing cells. Combined with well-established affinity chromatography purification methods, our approach contains faster, cost-efficient procedures for biofabrication in a well-known microbial cell factory and the purification of "ready-to-use" loaded protein nanoparticles, thereby opening the way to faster and easier engineering and production of vault-based DDSs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant vaccines in 2022, a perspective from the cell factory

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80's, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tuning plasmid DNA amounts for cost-effective transfections of mammalian cells, when less is more

  • Carreño, Aida|||0000-0001-7725-7515
  • Guerrero-Yagüe, Rubén|||0000-0002-6012-2734
  • Casal, Enriqueta|||0000-0002-0334-0380
  • Mendoza, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Transient gene expression (TGE) in mammalian cells is a well-known approach to the fast expression of recombinant proteins. The human cell line HEK (human embryonic kidney) 293F is widely used in this field, due to its adaptability to grow in suspension to high cell densities in serum-free media, amenability to transfection, and production of recombinant proteins in satisfactory quantities for functional and structural analysis. Amounts of plasmid DNA (pDNA) required in transfections for TGE remain high (usually 1 µg pDNA/mL, or even higher), representing a noticeable proportion of the overall cost. Thus, there is an economic need to reduce amounts of coding pDNA in TGE processes. In this work, amounts of both pDNA and transfecting agent used for TGE in HEK 293F cells have been explored in order to reduce them without compromising (or even improving) the productivity of the process in terms of protein yield. In our hands, minimal polyethyleneimine (PEI) cytotoxicity and optimum protein yields were obtained when transfecting at 0.5 µg pDNA/mL (equal to 0.5 µg pDNA/million cells) and a DNA-to-PEI ratio of 1:3, a trend confirmed for several unrelated recombinant proteins. Thus, carefully tuning pDNA and transfecting agent amounts not only reduces the economic costs but also results in higher recombinant protein yields. These results surely have a direct application and interest for the biopharmaceutical industry, always concerned in increasing productivity while decreasing economic costs. • Mammalian cells are widely used to produce recombinant proteins in short times. • Tuning DNA and transfecting agent are of great interest to optimize economic costs. • Reducing DNA and transfecting agent amounts result in higher protein yields.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior

  • Revilla, Giovanna|||0000-0003-2971-5651
  • Al Qtaish, Nuseibah|||0000-0001-5966-6155
  • Caruana Santiago, Pablo|||0000-0002-0170-4355
  • Sainz-Ramos, Myriam
  • Lopez-Mendez, Tania
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Paez-Espinosa, Verónica|||0000-0002-1145-3748
  • Li, Changda|||0000-0002-2847-3737
  • Fucui Vallverdú, Núria
  • Edwards, Maria
  • Moral, Antonio|||0000-0001-5551-0145
  • Pérez, José Ignacio
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Pedraz, José Luis|||0000-0002-3938-2267
  • Gallego, Idoia|||0000-0002-9312-8147
  • Corcoy i Pla, Rosa|||0000-0001-5055-6814
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Puras, Gustavo|||0000-0002-1536-7601
  • Mato, Eugènia|||0000-0001-8121-9335
Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formulations. The utilization of nanoparticles presents a viable option, as it allows for targeted drug delivery, reducing certain side effects and enhancing the overall quality of life for patients. This study aimed to produce and assess, both in vitro and in vivo, the cytotoxicity, biodistribution, and therapeutic efficacy of lenvatinib-loaded PLGA nanoparticles (NPs), both with and without decoration using antibody conjugation (cetuximab), as a novel therapeutic approach for managing aggressive thyroid tumors. Methods: Poly(lactic-co-glycolic acid) nanoparticles (NPs), decorated with or without anti-EGFR, were employed as a lenvatinib delivery system. These NPs were characterized for size distribution, surface morphology, surface charge, and drug encapsulation efficiency. Cytotoxicity was evaluated through MTT assays using two cellular models, one representing normal thyroid cells (Nthy-ori 3-1) and the other representing anaplastic thyroid cells (CAL-62). Additionally, an in vivo xenograft mouse model was established to investigate biodistribution and therapeutic efficacy following intragastric administration. Results: The NPs demonstrated success in terms of particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and cetuximab distribution across the surface. In vitro analysis revealed cytotoxicity in both cellular models with both formulations, but only the decorated NPs achieved an ID50 value in CAL-62 cells. Biodistribution analysis following intragastric administration in xenografted thyroid mice demonstrated good stability in terms of intestinal barrier function and tumor accumulation. Both formulations were generally well tolerated without inducing pathological effects in the examined organs. Importantly, both formulations increased tumor necrosis; however, decorated NPs exhibited enhanced parameters related to apoptotic/karyolytic forms, mitotic index, and vascularization compared with NPs without decoration. Conclusions: These proof-of-concept findings suggest a promising strategy for administering TKIs in a more targeted and effective manner.